门冬氨酸鸟氨酸联合醒脑静治疗肝性脑病患者疗效及其对血清炎症因子水平的影响

doi:10.3969/j.issn.1672-5069.2020.03.026

Abstract

Abstract: Objective The aim of this study was to observe the short-term efficacy of ornithine aspartate and a herbal compound, Xingnaojing, combination in treatment of patients with hepatitis B liver cirrhosis (LC) complicated by hepatic encephalopathy (HE) . Methods 62 hepatitis B-induced LC patients with HE were randomly divided into observation (n=31) and control group (n=31). The patients in the control group were treated with Xingnaojing, and those in the observation group were treated with ornithine aspartate at the basis of treatment in the control group. The regimen in both groups lasted for 2 weeks. Serum interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were detected by ELISA, and the cognitive functions were evaluated by number connection test (NCT), digital symbol (DS), mini-mental state examination (MMSE) and Hasegawa dementia scale (HDS). Results At the end of two week treatment, the fatality rate in observation group was 19.4%, significantly lower than 35.5%(P<0.05) in the control; after discontinuation of the regimen, the MMSE score in the observation was (28.1±3.2), significantly higher than 【(22.1±2.8), P<0.05】, the HDS score was (27.7±2.6), significantly higher than 【(19.0±2.1), P<0.05】, the DS score was (60.7±1.9), much higher than 【(43.1±4.0),P<0.05】, while the time of NCT was (51.6±5.9)s, significantly shorter than 【(62.4±6.5)s, P<0.05】 in the control; serum IL-6 level in the observation was (11.8±0.9)ng/L, much lower than 【(14.9±1.0)ng/L, P<0.05】, serum CRP level was (13.6±1.7)ng/L, significantly lower than 【(15.5±1.9)ng/L, P<0.05】, and serum TNF-α levels was (12.0±1.0)ng/L, significantly lower than 【(15.9±1.2)ng/L, P<0.05】 in the control; blood ammonia level in the observation was (54.9±5.6)μmol/L, significantly lower than 【(85.3±8.7)μmol/L, P<0.05】 in the control, while there were no significant differences as respect to total serum bilirubin and albumin levels between the two groups (P<0.05). Conclusion The use of isophanate ornithine and Xingnaojing combination is effective in the treatment of patients with LC and HE, which might inhibit the inflammatory reaction and decrease blood NH3 levels.

Key words: Liver cirrhosis, Hepatic encephalopathy, Ornithine aspartate, Herbal medicine, Blood ammonia, Cognitive functions, Therapy

Sun Huiqing, Zhang Shufeng, Cui Shilan, et al.. Short-term efficacy of ornithine aspartate and a herbal compound combination in treatment of patients with hepatitis B liver cirrhosis complicated by hepatic encephalopathy[J]. Journal of Practical Hepatology, 2020, 23(3): 405-408.

References

[1] 陈东风, 孙文静. 肝性脑病的新认识-从指南到临床. 实用肝脏病杂志, 2016, 19(1): 16-19.
[2] Hassan SS, Baumgarten TJ, Ali AM, et al. Hepatic encephalopathy. Clin Neurophysiol, 2019, 130(6): 886-892.
[3] Kim D, Shin BS, Song I, et al. Relationship between intraoperative bispectral index and consciousness recovery in patients with hepatic encephalopathy undergoing liver transplant: a retrospective analysis. Transplant Proc, 2019, 51(3): 798-804.
[4] Mikulski T, Dabrowski J, Hilgier W, et al. Effects of supplementation with branched chain amino acids and ornithine aspartate on plasma ammonia and central fatigue during exercise in healthy men. Folia Neuropathol, 2015, 53(4): 377-386.
[5] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Metab Brain Dis, 2016, 31(6): 1365-1367.
[6] Kircheis G. Current state of knowledge of hepatic encephalopathy (part v): clinical efficacy of l-ornithine-l-aspartate in the management of HE. Virus Dis, 2018, 29(4): 468-477.
[7] Shawcross DL, Dunk AA, Jalan R, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol, 2016, 28(2): 146-152.
[8] Sharma K, Pant S, Misra S, et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol, 2014, 20(4): 225-232.
[9] Varakanahalli S, Sharma BC, Srivastava S, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of l-ornithine l-aspartate versus placebo. Eur J Gastroenterol Hepatol, 2018, 30(8): 951-958.
[10] Butterworth RF. L-ornithine l-aspartate (lola) for the treatment of hepatic encephalopathy in cirrhosis: novel insights and translation to the clinic. Drugs, 2019, 79(1): 1-3.
[11] 孙晓. 微生态制剂联合肠内营养治疗肝性脑病患者营养学及血清指标的变化. 实用肝脏病杂志, 2017, 20(6): 777-778.
a) Hadjihambi A, Arias N, Sheikh M, et al. Hepatic encephalopathy: a critical current review. Hepatol Int, 2018, 12(1): 135-147.
[12] Zhu GQ, Shi KQ, Huang S, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther, 2015, 41(7): 624-635.
[13] Canbay A, Sowa JP. L-ornithine l-aspartate (lola) as a novel approach for therapy of non-alcoholic fatty liver disease. Drugs, 2019, 79(1): 39-44.
[14] Suraweera D, Sundaram V, Saab S. Evaluation and management of hepatic encephalopathy: current status and future directions. Gut Liver, 2016, 10(4): 509-519.
[15] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the European association for the study of the liver. Hepatology, 2014, 60(2): 715-735.
[16] Zhang Y, Liu FQ, Yue ZD, et al. Safety and efficacy of transfemoral intrahepatic portosystemic shunt for portal hypertension: A single-center retrospective study. World J Clin Cases, 2019, 7(12): 1410-1420.
[17] Maslennikov R, Driga A, Ivashkin K, et al. NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis. Gastroenterol Hepatol Bed Bench,2018,11(4):325-332.
[18] Ahn JO, Li Q, Lee YH, et al. Hyperammonemic hepatic encephalopathy management through l-ornithin-l-aspartate administration in dogs. J Vet Sci, 2016, 17(3):431-433.
[19] McMillin M, Grant S, Frampton G, et al. Elevated circulating TGFβ1 during acute liver failure activates TGFβ2 on cortical neurons and exacerbates neuroinflammation and hepatic encephalopathy in mice. J Neuroinflammation, 2019, 16(1): 69.

Short-term efficacy of ornithine aspartate and a herbal compound combination in treatment of patients with hepatitis B liver cirrhosis complicated by hepatic encephalopathy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ai Guo, Wang Ming, Zhu Jiling, et al.. Preliminary study on the clinical efficacy of N-acetylcysteine in the treatment of patients with chronic icteric hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(3): 336-339.
[2]	Fang Lijuan, Wu Xiongfei. Application ofentecavir in the treatment of patients with hepatitis B virus carrier and pulmonary tuberculosis during antituberculotic therapy [J]. Journal of Practical Hepatology, 2020, 23(3): 340-343.
[3]	Fu Chuishi,Zhang Jiewei. Virological and biochemical response in children with chronic hepatitis C by using peginterferon-α2a and ribavirin combination treatment [J]. Journal of Practical Hepatology, 2020, 23(3): 344-347.
[4]	Du Ying, Jiang Zhihong, Wu Yaling. Efficacy of tripterygium wilfordii polyglycosides and magnesium isoglycyrrhizinate combination in the treatment of children with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2020, 23(3): 348-351.
[5]	Zhang Ming, Pu Lin, Xiong Haofeng, et al.. Comparison of KDIGO and ICA criteria in diagnosing acute kidney injury in critically ill cirrhotic patients [J]. Journal of Practical Hepatology, 2020, 23(3): 392-396.
[6]	Kang Xiao, Yu Li, Wang Lei, et al.. Value of endoscopic ultrasonography in diagnosis of esophagogastric varices in patients with hepatitisB liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(3): 397-400.
[7]	Rinat·Kirim, Turganaili·Aj, Shao Yinmei.. Clinical characteristics and risk factors of portal vein thrombosisin patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(3): 401-404.
[8]	Zhang Xiaowei, Zhong Rui. Short-term efficacy and tolerance ofsofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection [J]. Journal of Practical Hepatology, 2020, 23(2): 191-194.
[9]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[10]	Wang Hongxue, Zhu Qingjing, Zhang Yujuan , et al. Efficacy of cetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries [J]. Journal of Practical Hepatology, 2020, 23(2): 227-230.
[11]	Li Yongchao, Ren Hongjun, Liu Lei, et al. Clinical efficacy of double plasma adsorption and plasma exchange in treatment of patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2020, 23(2): 236-239.
[12]	Jia Jiao, Wang Fang, Zhang Bo, et al. Efficacy of ursodeoxycholic acid combined with calcitriol in treatment of patients with primary biliary cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 240-243.
[13]	Zhang Huiyong, Wu Xiuxin, Xu Chengrun. Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites [J]. Journal of Practical Hepatology, 2020, 23(2): 244-247.
[14]	A Sigen, Xia Yijun, Wu Huijun, et al. Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2020, 23(2): 248-251.
[15]	Hu Xing, Meng Fankun, Han Jing, et al. Clinical value of echocardiography in evaluating cardiac structure and function in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 252-255.